New results to RG6206 molecule in boys with Duchenne Muskeldystrophy

Roche will be shared the clinical results at AAN 2019. Phase Ib/II study of the anti-myostatin adnectin RG6206 in ambulatory boys with DMD showing no drug-related safety findings leading to withdrawal from the study through 72 weeks of treatment.

Clinical Trails
NCT02515669
RO7239361 (BMS-986089)

#DMD #Duchenne Muskeldystrophie #Duchennes Muskedystrofi #Duchenne Muscular Dystrophy

Publisert av

Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg Instagram

Ein tanke om “New results to RG6206 molecule in boys with Duchenne Muskeldystrophy”

  1. Last Update Posted : November 19, 2019

    Phase 1/2:
    RG6206 was well tolerated during the DB and OL phases of the study; none of the boys left the study due to a reaction related to RG6206.

    More Details

Innlegget er stengt for innspel.